DANOCRINE Drug Patent Profile
✉ Email this page to a colleague
When do Danocrine patents expire, and when can generic versions of Danocrine launch?
Danocrine is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in DANOCRINE is danazol. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the danazol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Danocrine
A generic version of DANOCRINE was approved as danazol by BARR on August 9th, 1996.
Summary for DANOCRINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 53 |
Clinical Trials: | 6 |
Patent Applications: | 4,597 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DANOCRINE at DailyMed |
Recent Clinical Trials for DANOCRINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sierra Oncology, Inc. | Phase 3 |
Peking University People's Hospital | Phase 1/Phase 2 |
Mayo Clinic | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for DANOCRINE
US Patents and Regulatory Information for DANOCRINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | DANOCRINE | danazol | CAPSULE;ORAL | 017557-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | DANOCRINE | danazol | CAPSULE;ORAL | 017557-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | DANOCRINE | danazol | CAPSULE;ORAL | 017557-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |